biotech

Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Here are five biotech stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny...
These five super-aggressive biotech stocks are all rated Buy at well-known Wall Street firms and are suitable for very aggressive investors that have a high-risk tolerance.
Frequency Therapeutics shares were absolutely crushed on Tuesday but saw a bit of a recovery early Wednesday.
Here are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Rubius Therapeutics was one of Monday’s biggest winners after it announced initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Novavax stock jumped to close out the week after the firm announced the final efficacy numbers for its COVID-19 vaccine candidate.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.